Go-ahead for LCT

By Dylan Bushell-Embling
Tuesday, 21 October, 2008

Living Cell Technologies [ASX: LCT] has received approval from the New Zealand Government to conduct a Phase I/IIa clinical trial of DiabeCell.

NZ's Health Minister, David Cunliffe, has approved the company's application, with the project to be monitored by his ministry.

A parallel Phase I/IIa trial commenced in Russia in 2007.

According to LCT, approval from the NZ Government will also make it easier to obtain approvals to trial the product in other companies.

DiabeCell uses insulin-producing porcine islet cells stored within LCT's proprietary encapsulation technology.

Content from other channels on our network

How Floor Scrubbers Support Infection Prevention In Healthcare

The AI Revolution in Clinical Trials: New Research Reveals Why Industry Leaders Are Making the Shift Now

Hospital’s "recovery at work" collaborative approach proves a winning model

Medicine shortages are testing Australia's health system and clinicians need national support

A Day in the Life of a home support clinical care team manager

HVAC&R behind the scenes of food: the systems, skills and standards shaping the next decade

Machinery Regulation will be Mandatory in Less Than a Year — Are You Ready?

Swisslog's multi-temperature automation modernises cold storage and logistics

Reading Between the Lines: A Smarter Way to Verify Allergen Safety

Clariant achieves EU approval for renewable additives in food-contact plastics

Sustainability Business Live: where compliance, risk and commercial strategy come together

$10m project to safeguard WA water supplies

Supermarket giant now powered using 100% renewables

CAWSYD26 to spotlight local climate solutions

Chip makes pH measurements easier